Across TCGA pan-cancer cohorts, CSMD2-AS1 RNA differs between tumor and matched normal tissue in 2 of 18 cancer types tested, making tumor–normal expression one of CSMD2-AS1’s most consistent transcriptional readouts.
The strongest signal is observed in breast invasive carcinoma (BRCA), where CSMD2-AS1 RNA is more highly expressed in tumor relative to normal tissue. In most cancer types CSMD2-AS1 is over-expressed in tumor.
BRCA and LUAD are the cancer types where CSMD2-AS1 tumor–normal differential expression is most reproducible.